456 related articles for article (PubMed ID: 29209327)
1. Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.
Hargadon KM
Front Immunol; 2017; 8():1594. PubMed ID: 29209327
[TBL] [Abstract][Full Text] [Related]
2. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation.
Sosa Cuevas E; Saas P; Aspord C
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190135
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells.
Fujii SI; Shimizu K
Front Immunol; 2017; 8():886. PubMed ID: 28824620
[TBL] [Abstract][Full Text] [Related]
6. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G
Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496
[TBL] [Abstract][Full Text] [Related]
8. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
[TBL] [Abstract][Full Text] [Related]
10. Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.
Sadozai H; Gruber T; Hunger RE; Schenk M
Front Immunol; 2017; 8():1617. PubMed ID: 29276510
[TBL] [Abstract][Full Text] [Related]
11. Modulation of innate immunity in the tumor microenvironment.
Gonzalez-Gugel E; Saxena M; Bhardwaj N
Cancer Immunol Immunother; 2016 Oct; 65(10):1261-8. PubMed ID: 27344341
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
13. Human CD141
Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
[TBL] [Abstract][Full Text] [Related]
14. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
15. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence.
Li M; Guo R; Wei J; Deng M; Li J; Tao Y; Li M; He Q
Acta Biomater; 2021 Dec; 136():546-557. PubMed ID: 34536603
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.
Vandenberk L; Belmans J; Van Woensel M; Riva M; Van Gool SW
Front Immunol; 2015; 6():663. PubMed ID: 26834740
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
18. Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.
Zhang XW; Huck K; Jähne K; Cichon F; Sonner JK; Ufer F; Bauer S; Woo MS; Green E; Lu K; Kilian M; Friese MA; Platten M; Sahm K
Oncoimmunology; 2021 May; 10(1):1920739. PubMed ID: 34026332
[TBL] [Abstract][Full Text] [Related]
19. Metastatic melanoma and immunotherapy.
Herzberg B; Fisher DE
Clin Immunol; 2016 Nov; 172():105-110. PubMed ID: 27430520
[TBL] [Abstract][Full Text] [Related]
20. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
